ICDM 2023

RS1 Research group on development of new drug and technology on metabolic disease The recent paradigm for research and development of new medicine and technology in metabolic disorder Chair(s): Choon Hee Chung, Gwanpyo Koh
Thursday 19 October, 15:30~16:50
Room 1 (3F)

This session entitled with 'The recent paradigm for research and development of new medicine and technology in metabolic disorder' is translational session and designed to provide a place for clinicians and basic researchers on development of new drug and technology on metabolic disease to understand the novel pathogenesis and potential therapeutic targets for metabolic diseases. In this session, discovery of a peripheral 5HT2A antagonist as a clinical candidate for nonalcoholic steatohepatitis (NASH), Rho-kinase is a molecular target for fatty liver diseases, ILDONG's new drug development program for the metabolic diseases and the searching process for biomarkers predicting diabetes and complications will be comprehensively discussed. This session will enhance the understanding for the recent advancement for novel drugs and technology of metabolic diseases.

RS1-1 Jin Hee Ahn GIST, Korea: Discovery of a new NASH clinical candidate

RS1-2 Young-Bum Kim Harvard University, USA: Rho-kinase is a molecular target for fatty liver diseases

RS1-3 Sung Goo Choi Ildong Pharmaceutical, Korea: ILDONG's new drug development program for metabolic diseases

RS1-4 Ho Chan Cho Keimyung University, Korea: The searching process for biomarkers predicting diabetes and complications

Panel discussion

RS1-Panel 1
Seung-Soon Im Keimyung University, Korea
RS1-Panel 2
Dughyun Choi Soonchunhyang University, Korea
RS1-Panel 3
Sunghwan Suh Sungkyunkwan University, Korea

RS2 Research group on beta cell biology and islet transplantation & AIBIS joint session Journey to overcome diabetes: insights through islet biology and xenotransplantation Chair(s): Ki-Ho Song, Jeong Hyun Park
Thursday 19 October, 15:30~16:50
Room 3 (3F)

The advancement of diverse scientific and technological fields has yielded a plethora of tools for delving deeper into the understanding of beta cells. Biogenetic engineering, in particular, has played a significant role, spanning from stem cell research to xenotransplantation. This session aims to present recent studies focusing on the characterization, differentiation, and dysfunction of beta cells, as well as the broader landscape of islet biology. Furthermore, we will explore groundbreaking discoveries in the field of xenotransplantation and delve into strategies for surmounting the limitations in clinical applications. Throughout this session, a comprehensive viewpoint will be offered, encompassing cutting-edge research spanning from the pathophysiology of diabetes involving in islet biology to the realm of islet transplantation.

RS2-1 Byung Joon Kim Gachon University, Korea: Islet xenotransplantation: unlocking the new possibility in diabetes care

RS2-2 Miriam Cnop Universite Libre de Bruxelles, Belgium: Endoplasmic reticulum stress causes beta cell failure in monogenic and polygenic diabetes

RS2-3 Takeshi Miyatsuka Kitasato University, Japan: Heterogeneity of islet cells during embryogenesis and differentiation

RS2-4 Shun-ichiro Asahara Kobe University, Japan: Role of mTORC1 in the regulation of pancreatic beta cell mass

RS3 Research group on energy metabolism Intertwined pathophyisology of diabetes and NAFLD Chair(s): Dae Ho Lee, Kae Won Cho
Thursday 19 October, 15:30~16:50
Room 4 (2F)

In recent years, emerging evidence has highlighted various intertwining mechanisms that link diabetes and NAFLD. This session aims to delve into cutting-edge research focusing on four key topics that explore the intricate inter-organ connections. The session will provide attendees with a comprehensive overview of pathophysiology of diabetes and NAFLD, showcasing cutting-edge research and novel insights into the molecular mechanisms that connect these two metabolic conditions. By understanding the molecular mechanism and interconnections among islet cells, intestine, adipose tissue, and the liver, researchers and clinicians can work collaboratively to develop targeted and effective treatments for individuals suffering from the concomitant burden of diabetes and NAFLD.

RS3-1 Dayoung Oh UT Southwestern Medical Center, USA: Regulation of GPR92-mediated intercellular communication in islets

RS3-2 Won-Il Jeong KAIST, Korea: Hepatic glutamate-mediated steatosis and inflammation

RS3-3 Sungsoon Fang Yonsei University, Korea: Intestinal FXR agonism modulates inter-organ crosstalk between intestine and adipose tissue to maintain glucose homeostasis

RS3-4 Hail Kim KAIST, Korea: Selective hepatic insulin resistance is not selective; serotonergic regulation of hepatic insulin signaling

RS4 Research group on diabetic vascular biology Integration of biology and epidemiology in diabetic vascular diseases Chair(s): Soon Hee Lee, Hyuk-Sang Kwon
Thursday 19 October, 15:30~16:50
Room 5 (2F)

Vascular diseases associated with diabetes are the leading cause of multi-organ damage, including renal failure, blindness, and atherosclerosis, and account for disabilities and high mortality rates in patients with diabetes. This session will introduce the first report on the Korean epidemiological fact sheets on diabetic vasculopathy and provide novel pathogenic mechanisms for vascular diseases demonstrated by several advanced technologies.

RS4-1 Jin Hwa Kim Chosun University, Korea: Diabetic vascular complications factsheet in Korea

RS4-2 Hanjoong Jo Emory University, USA: Blood Flow-Induced Reprograming of Endothelial cells (FIRE) in atherosclerosis

RS4-3 Junyeop Lee University of Ulsan, Korea: Novel concepts in the pathogenesis of diabetic vasculopathy

Panel discussion

RS4-Panel 1
Sang Soo Kim Pusan National University, Korea
RS4-Panel 2
Chang Hee Jung University of Ulsan, Korea

RS5 Research group on fatty liver disease The NAFLD era: where we are Chair(s): Cheol-Young Park, Mi-Kyung Kim
Thursday 19 October, 16:50~18:10
Room 3 (3F)

This session will cover diabetes and NAFLD from basic to clinical. Earlier in the session, speakers will talk about the first Korean fatty liver & diabetes statistics and assessment and management of diabetes & NAFLD. Later in the session, speakers will talk about drug screening strategies and developmental pathways of NAFLD using animal models.

RS5-1 Eugene Han Keimyung University, Korea: Fatty liver & diabetes statics in Korea 2009-2017

RS5-2 Terry Cheuk-Fung Yip The Chinese University of Hong Kong, China: Building a clinical care pathway for diabetes and NAFLD

RS5-3 Ji Hee Yu Korea University, Korea: Drug screening strategies using the zebrafish model for NAFLD

RS5-4 Utpal Pajvani Columbia University, USA: Maladaptive regeneration - the reawakening of developmental pathways in the obese liver

RS6 Research group on genetics Polygenic risk scores - is it ready to be used in the clinic? Chair(s): Sung-Hoon Kim, Jae Hyuk Lee
Thursday 19 October, 16:50~18:10
Room 4 (2F)

The session for the research group on genetics will focus on the readiness of Polygenic Risk Scores (PRS) for clinical use. We will begin by exploring the methods employed in constructing PRS and their application in predicting diabetes and related complications. Our discussion will then shift to the commercial development of PRS, including the associated regulatory challenges. Lastly, we will address the complexities of identifying monogenic diabetes, a distinct and often misdiagnosed form of the disease. We eagerly anticipate a vibrant and insightful dialogue during the session.

RS6-1 Wonil Chung Soongsil University, Korea: Methods for constructing polygenic risk scores

RS6-2 Jae-Seung Yun The Catholic University of Korea, Korea: Polygenic risk scores for diabetes and related complications

RS6-3 Sungho Won Seoul National University, Korea: Risk prediction with polygenic risk score and updates from commercial genome-wide scans

RS6-4 Toni I. Pollin University of Maryland, USA: Issues in identifying monogenic diabetes

RS7 Research group on CGM and AID CGM for everyone: now with RCT evidence in Koreans Chair(s): Min Kyong Moon, Jae Hyeon Kim Thursday 19 October, 16:50~18:10 Room 5 (2F)

This is a session on the latest RCT evidence on CGM in Koreans covering individualized nutrition, type 2 diabetes with and without intensive insulin therapy, and automated insulin delivery (AID) in type 1 diabetes. As the first dedicated session organized by the Research Group on CGM and AID of Korean Diabetes Association, this session will help to understand the current evidence supporting the expanding role of CGM.

RS7-1 Hun Jee Choe Hallym University, Korea: Empowering diabetes management: leveraging patient-driven lifestyle modification with isCGM and the SEOUL Algorithm

RS7-2 Sang-Man Jin Sungkyunkwan University, Korea: T2DM with MDI and premixed insulin: results from the FreEdoM-2 trial

RS7-3 Jun Sung Moon Yeungnam University, Korea: Automated Insulin Delivery (AID): the first RCT evidence in Koreans

RS7-4 Sun Joon Moon Sungkyunkwan University, Korea: Individualized nutrition using CGM and Artificial Intelligence

	사전등록 (~2023년 9월 15일까지)		현장등록 (2023년 10월 19일~21일)
	KDA회원	비회원	KDA회원	비회원
전문의(개원의, 교수, 봉직의, 전임의 포함)	₩280,000	₩350,000	₩370,000	₩450,000
전공의, 간호사, 영양사, 사회복지사, 약사, 연구원, 운동처방사 및 기타 (군의관 및 공중보건의 포함)	₩180,000	₩230,000	₩250,000	₩270,000
저녁 식사	₩30,000

Program details

평점안내 (For Korean)